{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:04:35Z","timestamp":1771553075545,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Foundation of Xinjiang Uygur Autonomous Region Introduction plan of \"Tianchi Talents\", Natural Science Support Program of Xinjiang Production and Construction Corps","award":["grant 2024DA048"],"award-info":[{"award-number":["grant 2024DA048"]}]},{"name":"Shihezi University Research Program for Top-Notch Young Scholars","award":["grant BJZK202407"],"award-info":[{"award-number":["grant BJZK202407"]}]},{"name":"the Shihezi University High-Level Talents\u2019 Research Initiation Project","award":["grant 2022ZK020 and RCZK202445"],"award-info":[{"award-number":["grant 2022ZK020 and RCZK202445"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Sci Food"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder with limited treatment options. This study investigated the therapeutic potential of water extract of\n                    <jats:italic>Ajania fruticulosa<\/jats:italic>\n                    (WEAF) against NAFLD in cellular and animal models. WEAF significantly attenuated obesity, lipid accumulation, liver injury, and inflammation in NAFLD mice. Next, UPLC-MS\/MS-based network pharmacology and molecular biology revealed that WEAF alleviated NAFLD by TLR2-mediated MYD88\/NF-\u03baB and SREBP1\/PPAR-\u03b3 pathways, with 3,4-dihydroxyphenylpropionic acid, glycitein, and isorhapontigenin identified as the primary bioactive compounds. Finally, molecular docking, molecular dynamics, drug affinity responsive target stability, and cellular thermal shift assay confirmed that glycitein and isorhapontigenin directly bind to TLR2 to modulate the NF-\u03baB\/PPAR-\u03b3 signaling, and their anti-NAFLD effects were abolished by TLR2 agonist Pam3CSK4. In conclusion, WEAF and its key active compounds, glycitein and isorhapontigenin, effectively ameliorate obesity-induced NAFLD via the NF-\u03baB\/PPAR-\u03b3 signaling pathway by targeting TLR2, supporting their potential as therapeutic target and agents for NAFLD.\n                  <\/jats:p>","DOI":"10.1038\/s41538-026-00722-w","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T17:34:04Z","timestamp":1769189644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Computational-experimental study reveals direct target and bioactives of Ajania fruticulosa against NAFLD via TLR2\/NF-\u03baB\/PPAR-\u03b3 signaling"],"prefix":"10.1038","volume":"10","author":[{"given":"Chaoyue","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisha","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awaguli","family":"Dawuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyan","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamatjan","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kashif","family":"Kashmiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhancang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saimijiang","family":"Yaermaimaiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abudumijiti","family":"Abulizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"722_CR1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851\u2013861 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"722_CR2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","volume":"79","author":"MH Le","year":"2023","unstructured":"Le, M. H. et al. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J. Hepatol. 79, 287\u2013295 (2023).","journal-title":"J. Hepatol."},{"key":"722_CR3","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s11427-023-2494-x","volume":"67","author":"S Li","year":"2024","unstructured":"Li, S., Mehal, W. Z. & Ouyang, X. RNA modifications in the progression of liver diseases: from fatty liver to cancer. Sci. China Life Sci. 67, 2105\u20132119 (2024).","journal-title":"Sci. China Life Sci."},{"key":"722_CR4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41587-024-02215-1","volume":"42","author":"M Eisenstein","year":"2024","unstructured":"Eisenstein, M. Startups probe hidden viruses in the \u2018dark genome\u2019 to treat disease. Nat. Biotechnol. 42, 539\u2013541 (2024).","journal-title":"Nat. Biotechnol."},{"key":"722_CR5","doi-asserted-by":"crossref","unstructured":"Administration USFaD. Wegovy approved for MASH. Nat. Biotechnol. 43, 1404 (2025).","DOI":"10.1038\/s41587-025-02828-0"},{"key":"722_CR6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908\u2013922 (2018).","journal-title":"Nat. Med."},{"key":"722_CR7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13578-020-00507-y","volume":"10","author":"X Li","year":"2020","unstructured":"Li, X. & Wang, H. A.-O. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. Cell Biosci. 10, 140 (2020).","journal-title":"Cell Biosci."},{"key":"722_CR8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster, S., Cabrera, D., Arrese, M. & Feldstein, A. E. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15, 349\u2013364 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"722_CR9","volume":"39","author":"JQ Lei","year":"2025","unstructured":"Lei, J. Q. et al. Resveratrol alleviates liver fibrosis by targeting cross-talk between TLR2\/MyD88\/ERK and NF-\u03baB\/NLRP3 inflammasome pathways in macrophages. J. Biochem. Mol. Toxicol. 39, e70208 (2025).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"722_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41572-018-0019-2","volume":"4","author":"HKBR Seitz","year":"2018","unstructured":"Seitz, H. K. B. R. et al. Alcoholic liver disease. Nat. Rev. Dis. Prim. 4, 17 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"722_CR11","doi-asserted-by":"crossref","first-page":"603926","DOI":"10.3389\/fphar.2020.603926","volume":"11","author":"C Peng","year":"2020","unstructured":"Peng, C. et al. Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments. Front. Pharmacol. 11, 603926 (2020).","journal-title":"Front. Pharmacol."},{"key":"722_CR12","volume":"88","author":"W Sun","year":"2021","unstructured":"Sun, W. et al. A network pharmacology approach: inhibition of the NF-\u03baB signaling pathway contributes to the NASH preventative effect of an Oroxylum indicum seed extract in oleic acid-stimulated HepG2 cells and high-fat diet-fed rats. Phytomedicine 88, 153498 (2021).","journal-title":"Phytomedicine"},{"key":"722_CR13","volume":"15","author":"Z Guo","year":"2024","unstructured":"Guo, Z. et al. Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications. Front. Immunol. 15, 1336493 (2024).","journal-title":"Front. Immunol."},{"key":"722_CR14","volume":"16","author":"B Yang","year":"2025","unstructured":"Yang, B. et al. Correlation between liver fibrosis in non-alcoholic fatty liver disease and insulin resistance indicators: a cross-sectional study from NHANES 2017-2020. Front. Endocrinol. 16, 1514093 (2025).","journal-title":"Front. Endocrinol."},{"key":"722_CR15","doi-asserted-by":"crossref","first-page":"1502751","DOI":"10.3389\/fmicb.2024.1502751","volume":"15","author":"VBC Kumari","year":"2025","unstructured":"Kumari, V. B. C. et al. Fermented sugarcane juice-derived probiotic Levilactobacillus brevis RAMULAB54 enhances lipid metabolism and glucose homeostasis through PPAR-\u03b3 activation. Front. Microbiol. 15, 1502751 (2025).","journal-title":"Front. Microbiol."},{"key":"722_CR16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.cmet.2024.01.011","volume":"36","author":"S Rong","year":"2024","unstructured":"Rong, S. et al. DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER. Cell Metab. 36, 617\u2013629.e7 (2024).","journal-title":"Cell Metab."},{"key":"722_CR17","volume":"31","author":"WY Nie","year":"2025","unstructured":"Nie, W. Y., Ye, Y., Tong, H. X. & Hu, J. Q. Herbal medicine as a potential treatment for non-alcoholic fatty liver disease. World J. Gastroenterol. 31, 100273 (2025).","journal-title":"World J. Gastroenterol."},{"key":"722_CR18","first-page":"1","volume":"40","author":"X Hao","year":"2021","unstructured":"Hao, X., Mingze, X. & Launched, Z. Transcriptome analysis for Ajania fruticulose from Sanjiangyuan Area. Chin. Wild Plant Resour. 40, 1\u20138+24 (2021).","journal-title":"Chin. Wild Plant Resour."},{"key":"722_CR19","first-page":"569","volume":"38","author":"J Shuya","year":"2023","unstructured":"Shuya, J. et al. Exploration of effective components and mechanism of anti - inflammatory activity of volatile oil of Tibetan Ajania fruticulosa by GC-MS and network pharmacology. West China J. Pharm. Sci. 38, 569\u2013574 (2023).","journal-title":"West China J. Pharm. Sci."},{"key":"722_CR20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/cbdv.201500377","volume":"13","author":"JY Liang","year":"2016","unstructured":"Liang, J. Y. et al. Chemical constituents and insecticidal activities of Ajania fruticulosa essential oil. Chem. Biodivers. 13, 1053\u20131057 (2016).","journal-title":"Chem. Biodivers."},{"key":"722_CR21","doi-asserted-by":"crossref","unstructured":"Liang J.-Y. et al. Chemical constituents from the aerial parts of Ajania fruticulosa. Biochem. System. Ecol. 92, 104124 (2020).","DOI":"10.1016\/j.bse.2020.104124"},{"key":"722_CR22","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.cmet.2025.05.007","volume":"37","author":"F Ma","year":"2025","unstructured":"Ma, F. et al. Dietary-timing-induced gut microbiota diurnal oscillations modulate inflammatory rhythms in rheumatoid arthritis. Cell Metab. 37, 1454 (2025).","journal-title":"Cell Metab."},{"key":"722_CR23","volume":"1871","author":"H Zha","year":"2025","unstructured":"Zha, H. et al. Isorhapontigenin alleviates acetaminophen-induced liver injury by promoting fatty acid oxidation. Biochim. Biophys. Acta Mol. Basis Dis. 1871, 167575 (2025).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"722_CR24","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397, 2212\u20132224 (2021).","journal-title":"Lancet"},{"key":"722_CR25","volume":"25","author":"WA-OX Fu","year":"2025","unstructured":"Fu, W. A.-O. X. et al. Dietary Inflammatory index and its association with fatty liver disease: a study in obese and non-obese populations. BMC Gastroenterol. 25, 102 (2025).","journal-title":"BMC Gastroenterol."},{"key":"722_CR26","doi-asserted-by":"crossref","first-page":"1457598","DOI":"10.3389\/fendo.2024.1457598","volume":"15","author":"Y Xuan","year":"2024","unstructured":"Xuan, Y. et al. Elevated ALT\/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States. Front. Endocrinol. 15, 1457598 (2024).","journal-title":"Front. Endocrinol."},{"key":"722_CR27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41575-024-00915-2","volume":"21","author":"KP Matchett","year":"2024","unstructured":"Matchett, K. P., Paris, J., Teichmann, S. A.-O. & Henderson, N. A.-O. Spatial genomics: mapping human steatotic liver disease. Nat. Rev. Gastroenterol. Hepatol. 21, 646\u2013660 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"722_CR28","doi-asserted-by":"crossref","first-page":"109927","DOI":"10.1016\/j.compbiomed.2025.109927","volume":"189","author":"R Heo","year":"2025","unstructured":"Heo, R. et al. KNU-DTI: KNowledge United Drug-Target Interaction prediction. Comput. Biol. Med. 189, 109927 (2025).","journal-title":"Comput. Biol. Med."},{"key":"722_CR29","doi-asserted-by":"crossref","DOI":"10.1186\/s13020-024-01056-z","volume":"20","author":"Y Zhai","year":"2025","unstructured":"Zhai, Y. et al. Network pharmacology: a crucial approach in traditional Chinese medicine research. Chin. Med. 20, 8 (2025).","journal-title":"Chin. Med."},{"key":"722_CR30","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3390\/molecules29071494","volume":"29","author":"TA-O Mouskeftara","year":"2024","unstructured":"Mouskeftara, T. A.-O. et al. Lipidomic analysis of liver and adipose tissue in a high-fat diet-induced non-alcoholic fatty liver disease mice model reveals alterations in lipid metabolism by weight loss and aerobic exercise. Molecules 29, 1494 (2024).","journal-title":"Molecules"},{"key":"722_CR31","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti, E., Pinzani, M. & Tsochatzis, E. A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65, 1038\u20131048 (2016).","journal-title":"Metabolism"},{"key":"722_CR32","doi-asserted-by":"crossref","first-page":"1389967","DOI":"10.3389\/fimmu.2024.1389967","volume":"15","author":"H Gong","year":"2024","unstructured":"Gong, H. et al. Associations between systemic inflammation indicators and nonalcoholic fatty liver disease: evidence from a prospective study. Front. Immunol. 15, 1389967 (2024).","journal-title":"Front. Immunol."},{"key":"722_CR33","first-page":"1","volume":"2020","author":"K Pei","year":"2020","unstructured":"Pei, K. et al. An overview of lipid metabolism and nonalcoholic fatty liver disease. BioMed. Res. Int. 2020, 1\u201312 (2020).","journal-title":"BioMed. Res. Int."},{"key":"722_CR34","doi-asserted-by":"crossref","first-page":"102505","DOI":"10.1016\/j.arr.2024.102505","volume":"101","author":"A Ullah","year":"2024","unstructured":"Ullah, A. et al. Exploring cytokines dynamics: Uncovering therapeutic concepts for metabolic disorders in postmenopausal women- diabetes, metabolic bone diseases, and non-alcohol fatty liver disease. Ageing Res. Rev. 101, 102505 (2024).","journal-title":"Ageing Res. Rev."},{"key":"722_CR35","volume":"17","author":"H Yang","year":"2020","unstructured":"Yang, H. et al. Anti-inflammatory protein TSG-6 secreted by bone marrow mesenchymal stem cells attenuates neuropathic pain by inhibiting the TLR2\/MyD88\/NF-\u03baB signaling pathway in spinal microglia. J. Neuroinflammation 17, 154 (2020).","journal-title":"J. Neuroinflammation"},{"key":"722_CR36","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3389\/fimmu.2019.01843","volume":"10","author":"S Liu","year":"2019","unstructured":"Liu, S. et al. Influenza virus-induced robust expression of SOCS3 contributes to excessive production of IL-6. Front. Immunol. 10, 1843 (2019).","journal-title":"Front. Immunol."},{"key":"722_CR37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.biomaterials.2016.03.016","volume":"92","author":"V Mishra","year":"2016","unstructured":"Mishra, V. et al. Titanium dioxide nanoparticles augment allergic airway inflammation and Socs3 expression via NF-\u03baB pathway in murine model of asthma. Biomaterials 92, 90\u2013102 (2016).","journal-title":"Biomaterials"},{"key":"722_CR38","doi-asserted-by":"crossref","DOI":"10.1016\/j.sjbs.2022.103348","volume":"29","author":"I Ashfaq","year":"2022","unstructured":"Ashfaq, I., Sheikh, N., Fatima, N. & Tayyeb, A. Inhibition of anti-inflammatory pathway through suppressors of cytokine signalling (Socs2\/Socs3) in the initiation of hepatocellular carcinoma. Saudi J. Biol. Sci. 29, 103348 (2022).","journal-title":"Saudi J. Biol. Sci."},{"key":"722_CR39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/21623945.2020.1749495","volume":"9","author":"S Fang","year":"2020","unstructured":"Fang, S. et al. MiR-455 targeting SOCS3 improve liver lipid disorders in diabetic mice. Adipocyte 9, 179\u2013188 (2020).","journal-title":"Adipocyte"},{"key":"722_CR40","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1074\/jbc.M115.664706","volume":"291","author":"M Ruscica","year":"2016","unstructured":"Ruscica, M. et al. Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J. Biol. Chem. 291, 3508\u20133519 (2016).","journal-title":"J. Biol. Chem."},{"key":"722_CR41","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.jcmgh.2021.07.016","volume":"12","author":"Y Choi","year":"2021","unstructured":"Choi, Y. et al. Liver-specific deletion of mouse CTCF leads to hepatic steatosis via augmented PPAR\u03b3 signaling. Cell Mol. Gastroenterol. Hepatol. 12, 1761\u20131787 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"722_CR42","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4034922","volume":"2022","author":"H Liang","year":"2022","unstructured":"Liang, H. et al. Dietary histidine supplementation maintained amino acid homeostasis and reduced hepatic lipid accumulation of juvenile largemouth bass, Micropterus Salmoides. Aquac. Nutr. 2022, 4034922 (2022).","journal-title":"Aquac. Nutr."},{"key":"722_CR43","doi-asserted-by":"crossref","first-page":"114631","DOI":"10.1016\/j.fct.2024.114631","volume":"187","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. Toosendanin induces hepatotoxicity via disrupting LXR\u03b1\/Lipin1\/SREBP1 mediated lipid metabolism. Food Chem. Toxicol. 187, 114631 (2024).","journal-title":"Food Chem. Toxicol."},{"key":"722_CR44","volume":"25","author":"B Lyu","year":"2025","unstructured":"Lyu, B. et al. Target discovery driven by chemical biology and computational biology. Chem. Rec. 25, e202400182 (2025).","journal-title":"Chem. Rec."},{"key":"722_CR45","volume":"194","author":"Y-S Ren","year":"2021","unstructured":"Ren, Y.-S. et al. Drug affinity responsive target stability (DARTS) accelerated small molecules target discovery: principles and application. Biochem. Pharmacol. 194, 114798 (2021).","journal-title":"Biochem. Pharmacol."},{"key":"722_CR46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbrc.2023.05.038","volume":"667","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. TLR2 and CASP7 as the biomarkers associated with non-alcoholic fatty liver disease and chronic kidney disease. Biochem. Biophys. Res. Commun. 667, 50\u201357 (2023).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"722_CR47","doi-asserted-by":"crossref","first-page":"10555","DOI":"10.3390\/ijms251910555","volume":"25","author":"N Del Santos","year":"2024","unstructured":"Del Santos, N. et al. Impact of mygalin on inflammatory response induced by toll-like receptor 2 agonists and IFN-\u03b3 activation. Int. J. Mol. Sci. 25, 10555 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"722_CR48","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1021\/acs.jafc.3c09601","volume":"72","author":"X Fang","year":"2024","unstructured":"Fang, X. et al. Puerarin induces macrophage M2 polarization to exert antinonalcoholic steatohepatitis pharmacological activity via the activation of autophagy. J. Agric. Food Chem. 72, 7187\u20137202 (2024).","journal-title":"J. Agric. Food Chem."},{"key":"722_CR49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jare.2023.02.007","volume":"55","author":"X Dong","year":"2024","unstructured":"Dong, X. et al. Bavachinin protects the liver in NAFLD by promoting regeneration via targeting PCNA. J. Adv. Res. 55, 131\u2013144 (2024).","journal-title":"J. Adv. Res."},{"key":"722_CR50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5114\/ceh.2021.104387","volume":"7","author":"C Ruenes Domech","year":"2021","unstructured":"Ruenes Domech, C. et al. Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease. Clin. Exp. Hepatol. 7, 55\u201365 (2021).","journal-title":"Clin. Exp. Hepatol."},{"key":"722_CR51","doi-asserted-by":"crossref","DOI":"10.1186\/s13104-017-2617-6","volume":"10","author":"A Loch","year":"2017","unstructured":"Loch, A. et al. Generic atorvastatin is as effective as the brand-name drug (LIPITOR\u00ae) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC Res. Notes 10, 291 (2017).","journal-title":"BMC Res. Notes"},{"key":"722_CR52","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"}],"container-title":["npj Science of Food"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41538-026-00722-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41538-026-00722-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41538-026-00722-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:09:08Z","timestamp":1771549748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41538-026-00722-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1038\/s41538-026-00722-w","relation":{},"ISSN":["2396-8370"],"issn-type":[{"value":"2396-8370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}